Heidelberg Pharma AG
XETRA:HPHA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.17
3.85
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Heidelberg Pharma AG
Heidelberg Pharma AG
Total Receivables
Heidelberg Pharma AG
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Heidelberg Pharma AG
XETRA:HPHA
|
Total Receivables
€2.3m
|
CAGR 3-Years
15%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Total Receivables
€2.3B
|
CAGR 3-Years
139%
|
CAGR 5-Years
142%
|
CAGR 10-Years
N/A
|
|
|
MorphoSys AG
XETRA:MOR
|
Total Receivables
€30.8m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-12%
|
|
|
Immatics NV
NASDAQ:IMTX
|
Total Receivables
€5.7m
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Total Receivables
€171.8m
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
0%
|
|
|
Formycon AG
XETRA:FYB
|
Total Receivables
€28.3m
|
CAGR 3-Years
54%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
Heidelberg Pharma AG
Glance View
Heidelberg Pharma AG is a biopharmaceutical company, which engages in the research and development of drugs for cancer patients. The company is headquartered in Ladenburg, Baden-Wuerttemberg and currently employs 89 full-time employees. The company went IPO on 2006-11-13. The firm focuses on the research and development of therapy treatments for oncology area. The company aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. The company also offers preclinical contract research services.
See Also
What is Heidelberg Pharma AG's Total Receivables?
Total Receivables
2.3m
EUR
Based on the financial report for Nov 30, 2023, Heidelberg Pharma AG's Total Receivables amounts to 2.3m EUR.
What is Heidelberg Pharma AG's Total Receivables growth rate?
Total Receivables CAGR 5Y
30%
Over the last year, the Total Receivables growth was 60%. The average annual Total Receivables growth rates for Heidelberg Pharma AG have been 15% over the past three years , 30% over the past five years .
You don't have any saved screeners yet
